Farydak (Novartis): Global Drug Report 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Farydak" report has been added to ResearchAndMarkets.com's offering.

Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor.

Inhibition of HDAC leads to relaxed chromatin and increased transcription, causing accumulation of proteins and cell cycle arrest or apoptosis.

In preclinical development for multiple myeloma (MM), Farydak was able to overcome resistance to traditional drugs like dexamethasone and melphalan.

The drug also demonstrated the ability to enhance the efficacy of some established MM drugs, including Velcade (bortezomib; Takeda/Johnson & Johnson).

Early-stage development suggests that Farydak has very little effect as a monotherapy.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Farydak: Multiple myeloma

List of Figures

Figure 1: Farydak for multiple myeloma - SWOT analysis

Figure 2: The authors drug assessment summary of Farydak for multiple myeloma

Figure 3: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Farydak drug profile

Table 2: Farydak pivotal trial data in multiple myeloma

Table 3: Farydak early-phase trial data in multiple myeloma

Table 4: Farydak Phase II trial in multiple myeloma

Table 5: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/j69hvm

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs